Strs Ohio Acquires Shares of 14,857 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Strs Ohio purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 14,857 shares of the company's stock, valued at approximately $1,957,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. raised its stake in Neurocrine Biosciences by 6.6% in the 1st quarter. BlackRock Inc. now owns 13,466,650 shares of the company's stock valued at $1,363,094,000 after purchasing an additional 838,997 shares during the last quarter. State Street Corp raised its stake in Neurocrine Biosciences by 4.1% in the 2nd quarter. State Street Corp now owns 3,956,499 shares of the company's stock valued at $373,098,000 after purchasing an additional 156,584 shares during the last quarter. Geode Capital Management LLC grew its holdings in Neurocrine Biosciences by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 1,435,737 shares of the company's stock valued at $145,127,000 after buying an additional 47,042 shares during the period. DSM Capital Partners LLC grew its holdings in Neurocrine Biosciences by 15.4% in the 3rd quarter. DSM Capital Partners LLC now owns 1,224,017 shares of the company's stock valued at $137,702,000 after buying an additional 163,747 shares during the period. Finally, Woodline Partners LP grew its holdings in Neurocrine Biosciences by 189.0% in the 2nd quarter. Woodline Partners LP now owns 1,152,189 shares of the company's stock valued at $108,651,000 after buying an additional 753,495 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Mizuho lifted their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, February 8th. The Goldman Sachs Group lifted their price target on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a "buy" rating in a report on Thursday, January 25th. JPMorgan Chase & Co. lifted their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences has an average rating of "Moderate Buy" and a consensus price target of $139.67.

Neurocrine Biosciences Price Performance

Shares of NBIX traded down $0.54 during trading hours on Friday, reaching $132.00. 556,303 shares of the company's stock traded hands, compared to its average volume of 734,217. The firm has a market capitalization of $13.14 billion, a price-to-earnings ratio of 54.55 and a beta of 0.25. Neurocrine Biosciences, Inc. has a twelve month low of $89.04 and a twelve month high of $148.37. The business's fifty day simple moving average is $136.15 and its two-hundred day simple moving average is $127.22.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. Neurocrine Biosciences's revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 earnings per share. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current year.

Insider Buying and Selling

In related news, insider Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $145.06, for a total value of $725,300.00. Following the transaction, the insider now owns 7,507 shares of the company's stock, valued at approximately $1,088,965.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Neurocrine Biosciences news, insider Eric Benevich sold 19,818 shares of the firm's stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the sale, the insider now directly owns 40,778 shares in the company, valued at approximately $5,438,154.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $145.06, for a total value of $725,300.00. Following the sale, the insider now owns 7,507 shares of the company's stock, valued at $1,088,965.42. The disclosure for this sale can be found here. Insiders have sold a total of 196,994 shares of company stock valued at $27,205,009 over the last three months. Company insiders own 4.40% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.